

UNITED STATES PARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

			**asilingt	.011, 0.0. 20201	VB
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
08/945,459	12/09/97	MAKISHIMA		F	146.1275
Г	HM22/0524			EXAMINER	
BIERMAN MUSERLIAN AND LUCAS 600 THIRD AVENUE			ROMEO,D		
				ART UNIT	PAPER NUMBER
NEW YORK N	IY 10016			1647	25
				DATE MAILED:	05/24/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Office Action Summary

Application No. **08/945,459**

Applicantis

Makishima et al.

Examiner

David Romeo

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 18 Apr 2001 2b) This action is non-final. 2a) This action is FINAL. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 17-48 4a) Of the above, claim(s) _______ is/are withdrawn from consideration. 5) U Claim(s) ______ 6) Laim(s) is/are rejected. __ is/are objected to. 7) (Claim(s) are subject to restriction and/or election requirement. 8) X Claims 17-48 **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ______ is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved. 12) \square The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) \square All b) \square Some* c) \square None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 20) Other:

Application/Control Number: 08945459 Page 2

Art Unit: 1647

5

15

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 17-28, 41-47, drawn to a polypeptide and a pharmaceutical composition comprising same, classified in class 530, subclass 350.
 - II. Claims 29, 30-33, drawn to a plasmid encoding a polypeptide and a process of producing the encoded polypeptide, classified in class 435, subclass 320.1.
 - III. Claims 39-40, 48, drawn to a method of treatment comprising administering a polypeptide, classified in class 514, subclass 12.
- 10 2. The inventions are distinct, each from the other because of the following reasons:

The plasmid of Invention II is related to the polypeptide of Invention I by virtue of encoding same. The plasmid has utility for the recombinant production of the polypeptide in a host cell. Although the plasmid and polypeptide are related since the plasmid encodes the specifically claimed polypeptide, they are distinct inventions because they are physically and functionally distinct chemical entities, and the polypeptide product can be made by another and materially different process, such as by synthetic polypeptide synthesis or purification form the natural source. Further, the plasmid may be used for processes other than the production of the polypeptide, such as a nucleic acid hybridization assay.

Application/Control Number: 08945459 Page 3

Art Unit: 1647

5

10

15

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptide could be used an immunization protocol for the production of antibodies or in assays for agonists and antagonists thereto.

DR 5/23/1

The following pairwise combinations of products and methods are independent and distinct, wherein the respective products may neither be produced by, nor used in the respective methods: II and III.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. Because these inventions are distinct for the reasons given above and the searches required are not coextensive, restriction for examination purposes as indicated is proper.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. In addition, the inventions listed above as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or

Application/Control Number: 08945459

Art Unit: 1647

corresponding special technical features for the following reasons: the special technical feature of claim 17 is obvious over the prior of record for at least the reasons at paragraph 11, beginning at page 7, of the Office action mailed 6/30/2001 (Paper No. 20), and, alternatively, restriction is required under 35 U.S.C. 121 and 372, and, in accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Page 4

- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David S. Romeo whose telephone number is (703) 305-4050. The examiner can normally be reached on Monday through Friday from 6:45 a.m. to 3:15 p.m.

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

OFFICIAL PAPERS FILED BY FAX SHOULD BE DIRECTED TO (703) 308-4242.

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294.

ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.

08945459.025

15

5

10

20

Art Unit: 1647

WILLIA KANUN DAVID ROMEO PRIMARY EXAMINER ART UNIT 1647

May 23, 2001